While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

A novel pilot study, the TRIMM trial, is investigating if a GLP-1 agonist can eliminate minimal residual disease (MRD), as measured by ctDNA, in breast cancer patients with obesity. This frames a metabolic intervention as a potential anti-cancer therapeutic, moving beyond its role in supportive care.

Clinicians are hesitant to use insulin for PI3K inhibitor-induced hyperglycemia. The primary concern is that exogenous insulin, a potent growth factor, could theoretically counteract the therapy's anti-tumor effect by promoting cancer cell survival, although this risk remains unproven.

To prevent rebound weight gain and associated inflammation—which is particularly detrimental for cancer survivors—patients should not stop GLP-1s abruptly. Instead, a slow, methodical 20-week taper is recommended, with close monitoring to ensure weight stability before full discontinuation.

The common misconception that GLP-1s cause muscle loss is incorrect at a cellular level. Research shows GLP-1 receptor agonists directly promote muscle protein synthesis. Muscle loss is a secondary effect of appetite suppression and inadequate protein intake, not a direct action of the drug itself.

Early retrospective data from major cancer centers suggests patients on hormone therapy experience less weight loss with GLP-1 agonists. This indicates a potential drug interaction that may require clinicians to more closely monitor weight trends and consider dose adjustments for this patient population.

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

Beyond weight management, preliminary evidence suggests GLP-1 agonists may help with vasomotor symptoms (hot flashes) and arthralgia (joint pain). The proposed mechanism is indirect, likely through reduced inflammation from fat loss and less mechanical load on joints, representing a novel potential benefit for patients.

As the obesity market matures, the key differentiator may shift from maximum weight loss to tolerability. High discontinuation rates for GLP-1s due to GI side effects create an opportunity for drugs with slightly lower efficacy but a stellar safety profile, which could capture a large and underserved patient segment.